{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:12:45Z","timestamp":1793646765632,"version":"4.5.1"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:00:00Z","timestamp":1623888000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    Gastrointestinal (GI) tract graft-versus-host disease (GvHD) is a major cause of post-allo-HSCT (hematopoietic stem cell transplantation) morbidity and mortality. Patients with steroid-refractory GI-GvHD have a poor prognosis and limited therapeutic options. FMT2017002 trial (#NCT03148743) was a non-randomized, open-label, phase I\/II clinical study of FMT for treating patients with grade IV steroid-refractory GI-GvHD. A total of 55 patients with steroid-refractory GI-GvHD were enrolled in this study. Forty-one patients with grade IV steroid-refractory GI-GvHD were included in the final statistical analysis. Of them, 23 patients and 18 patients were assigned to the FMT group and the control group, respectively. On days 14 and 21 after FMT, clinical remission was significantly greater in the FMT group than in the control group. Within a follow-up period of 90 days, the FMT group showed a better overall survival (OS). At the end of the study, the median survival time was &amp;gt;539 days in the FMT group and 107 days in the control group (HR=3.51; 95% CI, 1.21\u201310.17;\n                    <jats:italic>p<\/jats:italic>\n                    =0.021). Both the event-free survival time (EFS) (HR=2.3, 95% CI, 0.99\u20135.4;\n                    <jats:italic>p<\/jats:italic>\n                    =0.08) and OS (HR=4.4, 95% CI, 1.5\u201313.04;\n                    <jats:italic>p<\/jats:italic>\n                    =0.008) were higher in the FMT group during the follow-up period. Overall, the mortality rate was lower in the FMT group (HR=3.97; 95% CI, 1.34\u201311.75;\n                    <jats:italic>p<\/jats:italic>\n                    =0.013). No differences in the occurrence of any other side effects were observed. Our data suggest that the diversity of the intestinal microbiota could be affected by allo-HSCT. Although its effectiveness and safety need further evaluation, FMT may serve as a therapeutic option for grade IV steroid-refractory GI-GvHD.\n                  <\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:uri>ClinicalTrials.gov<\/jats:uri>\n                      ], identifier [NCT03148743].\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2021.678476","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T06:45:17Z","timestamp":1623912317000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":61,"title":["Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial"],"prefix":"10.3389","volume":"12","author":[{"given":"Ye","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuewei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baoli","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Depei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,6,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-01-514786","article-title":"Acute GVHD: A Bench to Bedside Update","volume":"124","author":"Holtan","year":"2014","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra052638","article-title":"Hematopoietic Stem-Cell Transplantation","volume":"354","author":"Copelan","year":"2006","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02195","article-title":"Treating Steroid Refractory Intestinal Acute Graft-vs.-Host Disease With Fecal Microbiota Transplantation: A Pilot Study","volume":"9","author":"Qi","year":"2018","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-612747","article-title":"How I Treat Acute Graft-Versus-Host Disease of the Gastrointestinal Tract and the Liver","volume":"127","author":"McDonald","year":"2016","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000953","article-title":"Immunopathology and Biology-Based Treatment of Steroid-Refractory Graft-Versus-Host Disease","volume":"136","author":"Toubai","year":"2020","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2012.04.005","article-title":"First- and Second-Line Systemic Treatment of Acute Graft Versus Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation","volume":"18","author":"Martin","year":"2012","journal-title":"Biol Blood Marrow Transplant"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2014.69","article-title":"Prognostic Factors and Outcomes of Severe Gastrointestinal GVHD After Allogeneic Hematopoietic Cell Transplantation","volume":"49","author":"Castilla-Llorente","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.03179","article-title":"Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD","volume":"9","author":"K\u00f6hler","year":"2019","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/nature06244","article-title":"The Human Microbiome Project","volume":"449","author":"Turnbaugh","year":"2007","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112408","article-title":"Regulation of Intestinal Inflammation by Microbiota Following Allogeneic Bone Marrow Transplantation","volume":"209","author":"Jenq","year":"2012","journal-title":"J Exp Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/nri2515","article-title":"The Gut Microbiota Shapes Intestinal Immune Responses During Health and Disease","volume":"9","author":"Round","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-09-242784","article-title":"Graft-Versus-Host Disease: Regulation by Microbe-Associated Molecules and Innate Immune Receptors","volume":"115","author":"Penack","year":"2010","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/nri3535","article-title":"Microbiota-Mediated Colonization Resistance Against Intestinal Pathogens","volume":"13","author":"Bu\ufb03e","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.154351","article-title":"Repeated Fecal Microbiota Transplantations Attenuate Diarrhea and Lead to Sustained Changes in the Fecal Microbiota in Acute, Refractory Gastrointestinal Graft-Versus-Host-Disease","volume":"102","author":"Spindelboeck","year":"2017","journal-title":"Haematologica"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-717652","article-title":"Fecal Microbiota Transplantation for Patients With Steroid-Resistant Acute Graft-Versus-Host Disease of the Gut","volume":"28","author":"Kakihana","year":"2016","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.05.008","article-title":"Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook","volume":"149","author":"Kelly","year":"2015","journal-title":"Gastroenterology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2017.1290757","article-title":"Intestinal Microbiota, Fecal Microbiota Transplantation, and Inflammatory Bowel Disease","volume":"8","author":"Weingarden","year":"2017","journal-title":"Gut Microbes"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2014.133","article-title":"Fecal Microbiota Transplant for Treatment of Clostridium Difficile Infection in Immunocompromised Patients","volume":"109","author":"Kelly","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1205037","article-title":"Duodenal Infusion of Donor Feces for Recurrent Clostridium Difficile","volume":"368","author":"van Nood","year":"2013","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.03.070","article-title":"Adjunctive Fecal Microbiota Transplantation in Supportive Oncology: Emerging Indications and Considerations in Immunocompromised Patients","volume":"44","author":"Wardill","year":"2019","journal-title":"EBioMedicine"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.1112925.x","article-title":"Severity Index for Grading Acute Graft-Versus-Host Disease: Retrospective Comparison With Glucksberg Grade","volume":"97","author":"Rowlings","year":"1997","journal-title":"Br J Haematol"},{"key":"B22","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"B23","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12967-015-0646-2","article-title":"Step-Up Fecal Microbiota Transplantation Strategy: A Pilot Study for Steroid-Dependent Ulcerative Colitis","volume":"13","author":"Cui","year":"2015","journal-title":"J Transl Med"},{"key":"B24","doi-asserted-by":"publisher","first-page":"eaap9489","DOI":"10.1126\/scitranslmed.aap9489","article-title":"Reconstitution of the Gut Microbiota of Antibiotic-Treated Patients by Autologous Fecal Microbiota Transplant","volume":"10","author":"Taur","year":"2018","journal-title":"Sci Transl Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-04-638858","article-title":"Low Urinary Indoxyl Sulfate Levels Early After Transplantation Reflect a Disrupted Microbiome and are Associated With Poor Outcome","volume":"126","author":"Weber","year":"2015","journal-title":"Blood"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018017731","article-title":"Third-Party Fecal Microbiota Transplantation Following Allo-HCT Reconstitutes Microbiome Diversity","volume":"2","author":"DeFilipp","year":"2018","journal-title":"Blood Adv"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-Resistant E. Coli Bacteremia Transmitted by Fecal Microbiota Transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.678476\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T06:45:22Z","timestamp":1623912322000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.678476\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,17]]},"references-count":27,"alternative-id":["10.3389\/fimmu.2021.678476"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.678476","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,17]]},"article-number":"678476"}}